Abstract:ABSTRACT Cystic fibrosis (CF), an inherited genetic disorder caused by mutations in the cystic fibrosis transmembrane conductance regulator gene, results in sticky and thick mucosal fluids. This environment facilitates the colonization of various microorganisms, some of which can cause acute and chronic lung infections, while others may positively impact the disease. Rothia mucilaginosa , an oral commensal, is relatively abundant in the lungs of CF patients. Recent studies have unveiled its anti-inflammatory properties using in vitro three-dimensional lung epithelial cell cultures and in vivo mouse models relevant to chronic lung diseases. Apart from this, R. mucilaginosa has been associated with severe infections. However, its metabolic capabilities and genotype-phenotype relationships remain largely unknown. To gain insights into its cellular metabolism and genetic content, we developed the first manually curated genome-scale metabolic model, i RM23NL. Through growth kinetics and high-throughput phenotypic microarray testings, we defined its complete catabolic phenome. Subsequently, we assessed the model’s effectiveness in accurately predicting growth behaviors and utilizing multiple substrates. We used constraint-based modeling techniques to formulate novel hypotheses that could expedite the development of antimicrobial strategies. More specifically, we detected putative essential genes and assessed their effect on metabolism under varying nutritional conditions. These predictions could offer novel potential antimicrobial targets without laborious large-scale screening of knockouts and mutant transposon libraries. Overall, i RM23NL demonstrates a solid capability to predict cellular phenotypes and holds immense potential as a valuable resource for accurate predictions in advancing antimicrobial therapies. Moreover, it can guide metabolic engineering to tailor R. mucilaginosa ’s metabolism for desired performance. IMPORTANCE Cystic fibrosis (CF) is a genetic disorder characterized by thick mucosal secretions, leading to chronic lung infections. Rothia mucilaginosa is a common bacterium found in various parts of the human body, acting as a normal part of the flora. In people with weakened immune systems, it can become an opportunistic pathogen, while it is prevalent and active in CF airways. Recent studies have highlighted its anti-inflammatory properties in the lower pulmonary system, indicating the intricate relationship between microbes and human health. Herein, we have developed the first manually curated metabolic model of R. mucilaginosa . Our study examined the previously unknown relationships between the bacterium’s genotype and phenotype and identified essential genes that impact the metabolism under various conditions. With this, we opt for paving the way for developing new strategies in antimicrobial therapy and metabolic engineering, leading to enhanced therapeutic outcomes in cystic fibrosis and related conditions.

Genome-scale model of Rothia mucilaginosa predicts gene essentialities and reveals metabolic capabilities

Mechanistic Model of Rothia mucilaginosa Adaptation toward Persistence in the CF Lung, Based on a Genome Reconstructed from Metagenomic Data

Metabolic modelling as a powerful tool to identify critical components of Pneumocystis growth medium

Growing a cystic fibrosis-relevant polymicrobial biofilm to probe community phenotypes

Exploring the metabolic profile of A . baumannii for antimicrobial development using genome-scale modeling

A Comprehensive Genome-Scale Model for Rhodosporidium Toruloides IFO0880 Accounting for Functional Genomics and Phenotypic Data.

Tracking Polymicrobial Metabolism in Cystic Fibrosis Airways: Pseudomonas Aeruginosa Metabolism and Physiology Are Influenced by Rothia Mucilaginosa-Derived Metabolites

Genome-scale metabolic modeling of the human gut bacterium Bacteroides fragilis strain 638R

In vivo and in silico determination of essential genes of Campylobacter jejuni

Genome-Scale Metabolic Modeling Reveals Metabolic Alterations of Multidrug-Resistant Acinetobacter baumannii in a Murine Bloodstream Infection Model

Genome-scale metabolic modeling of Aspergillus fumigatus strains reveals growth dependencies on the lung microbiome

Exploring the Metabolic Network of the Epidemic Pathogen Burkholderia Cenocepacia J2315 Via Genome-Scale Reconstruction

Exploring the metabolic profiling of for antimicrobial development using genome-scale modelling

Constraints-based analysis identifies NAD+ recycling through metabolic reprogramming in antibiotic resistant Chromobacterium violaceum

Design of a proteolytic module for improved metabolic modeling of Bacteroides caccae

Development of a Polymicrobial Colony Biofilm Model to Test Antimicrobials in Cystic Fibrosis

METABOLIC MODELLING AS A POWERFUL TOOL TO IDENTIFY CRITICAL COMPONENTS OF GROWTH MEDIUM

Modeling Cystic Fibrosis Chronic Infection Using Engineered Mucus-like Hydrogels

A detailed genome-scale metabolic model of Clostridium thermocellum investigates sources of pyrophosphate for driving glycolysis

The Efficacy of an N-Acetylcysteine-Antibiotic Combination Therapy on Achromobacter xylosoxidans in a Cystic Fibrosis Sputum/Lung Cell Model

An in vitro medium for modeling gut dysbiosis associated with cystic fibrosis